Clinical Trial Update: Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of talimogene laherparepvec for recurrent breast cancer that cannot be removed surgically has been terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Inflammatory Breast Cancer

Drugs mentioned

• Talimogene laherparepvec (talimogene laherparepvec)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2023-01-25